Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells 5,387 Shares

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) insider Elizabeth Lin sold 5,387 shares of Tarsus Pharmaceuticals stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $80.00, for a total transaction of $430,960.00. Following the sale, the insider owned 13,320 shares in the company, valued at $1,065,600. This represents a 28.80% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Elizabeth Yeu Lin also recently made the following trade(s):

• On Wednesday, September 2nd, Elizabeth Lin sold 1,590 shares of Tarsus Pharmaceuticals stock. The stock was sold at an average price of $80.00, for a total transaction of $127,200.00.
• On Tuesday, September 1st, Elizabeth Lin sold 4,601 shares of Tarsus Pharmaceuticals stock. The shares were sold at an average price of $73.86, for a total value of $339,829.86.

Tarsus Pharmaceuticals Price Performance

Shares of NASDAQ TARS traded up $0.45 during midday trading on Thursday, reaching $83.21. 733,653 shares of the company traded hands, compared to its average volume of 744,913. Tarsus Pharmaceuticals, Inc. has a 12 month low of $48.20 and a 12 month high of $85.25. The firm has a market cap of $3.65 billion, a PE ratio of -76.34 and a beta of 0.54. The stock’s 50-day simple moving average is $65.08 and its 200-day simple moving average is $65.59. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.17 and a current ratio of 3.20.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.24). The firm had revenue of $173.91 million during the quarter, compared to analyst estimates of $169.65 million. Tarsus Pharmaceuticals had a negative net margin of 7.67% and a negative return on equity of 13.53%. As a group, equities analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -2.06 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. Parallel Advisors LLC lifted its stake in shares of Tarsus Pharmaceuticals by 139.2% during the 1st quarter. Parallel Advisors LLC now owns 500 shares of the company’s stock worth $35,000 after buying an additional 291 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in Tarsus Pharmaceuticals by 367.1% during the first quarter. PNC Financial Services Group Inc. now owns 710 shares of the company’s stock worth $50,000 after buying an additional 558 shares in the last quarter. Comerica Bank raised its position in Tarsus Pharmaceuticals by 470.0% during the fourth quarter. Comerica Bank now owns 855 shares of the company’s stock valued at $70,000 after purchasing an additional 705 shares in the last quarter. Truvestments Capital LLC boosted its stake in Tarsus Pharmaceuticals by 106.1% in the fourth quarter. Truvestments Capital LLC now owns 909 shares of the company’s stock valued at $74,000 after buying an additional 468 shares in the last quarter. Finally, State of Wyoming bought a new stake in shares of Tarsus Pharmaceuticals during the 2nd quarter valued at approximately $103,000. Institutional investors own 90.01% of the company’s stock.

Analyst Upgrades and Downgrades

TARS has been the topic of several research reports. Wall Street Zen lowered Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Mizuho lowered their price target on Tarsus Pharmaceuticals from $100.00 to $98.00 and set an “outperform” rating for the company in a research note on Friday, July 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Friday, July 17th. HC Wainwright reiterated a “buy” rating and set a $88.00 target price on shares of Tarsus Pharmaceuticals in a report on Thursday, July 9th. Finally, Oppenheimer boosted their price objective on shares of Tarsus Pharmaceuticals from $97.00 to $100.00 and gave the company an “outperform” rating in a research report on Wednesday, August 12th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Tarsus Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $90.50.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.